Type 1 diabetes is a chronic disease in which the immune system attacks and destroys insulin-producing beta cells in the pancreas, resulting in high blood levels of glucose. A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long-term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes. The researchers used an adeno-associated viral (AAV) vector to deliver to the mouse pancreas two proteins, Pdx1 and MafA, which reprogrammed plentiful alpha cells into functional, insulin-producing beta cells.
“This study is essentially the first description of a clinically translatable, simple single intervention in autoimmune diabetes that leads to normal blood sugars, and importantly with no immunosuppression,” says senior study author George Gittes of the University of Pittsburgh School of Medicine. “A clinical trial in both type 1 and type 2 diabetics in the immediate foreseeable future is quite realistic, given the impressive nature of the reversal of the diabetes, along with the feasibility in patients to do AAV gene therapy.”
Approximately 9% of the world’s adult population has diabetes, which can cause serious health problems such as heart disease, nerve damage, eye problems, and kidney disease. One fundamental goal of diabetes treatment is to preserve and restore functional beta cells, thereby replenishing levels of a hormone called insulin, which moves blood glucose into cells to fuel their energy needs. But in patients with type 1 diabetes, beta-cell replacement therapy is likely doomed to failure because the new cells might fall victim to the same autoimmunity that destroyed the original cells.
A potential solution to this problem is to reprogram other cell types into functional beta-like cells, which can produce insulin but are distinct from beta cells and therefore are not recognized or attacked by the immune system. To explore the feasibility of this approach, Gittes and first author Xiangwei Xiao of the University of Pittsburgh School of Medicine engineered an AAV vector to deliver to the mouse pancreas proteins called Pdx1 and MafA, which support beta cell maturation, proliferation, and function. The goal was to generate functional beta-like cells from pancreatic alpha cells, which may be the ideal source for beta cell replacement. For example, alpha cells are plentiful, resemble beta cells, and are in the correct location, all of which could facilitate reprogramming.
By comparing the gene expression patterns of normal beta cells and insulin-producing cells derived from alpha cells, the researchers confirmed nearly complete cellular reprogramming. This gene therapy approach restored normal blood glucose levels in diabetic mice for an extended period of time, typically around four months, and the new insulin-producing cells derived almost exclusively from alpha cells. Moreover, the strategy successfully generated functional insulin-producing cells from human alpha cells.
“The viral gene therapy appears to create these new insulin-producing cells that are relatively resistant to an autoimmune attack,” Gittes says. “This resistance appears to be due to the fact that these new cells are slightly different from normal insulin cells, but not so different that they do not function well.”
Several features of this approach could facilitate translation to humans. For one, AAV vectors like those used in this study are currently undergoing various gene therapy trials in humans. Moreover, the viral vectors can be delivered directly to the human pancreas through a routinely performed non-surgical endoscopic procedure; however, this procedure can elicit pancreatic inflammation. In addition, no immunosuppression is required, so patients would avoid related side effects such as an increased risk of infection.
However, one major concern was that the mice did eventually return to the diabetic state, suggesting that this treatment would not represent a definitive cure for the disease. “The protection from recurrent diabetes in the mice was not permanent, although some studies would suggest that processes in mice are highly accelerated, so four months in mice might translate to several years in humans,” Gittes says.
Currently, the researchers are testing their approach in primates. “If we are able to show efficacy in non-human primates, we will begin work with the FDA to get approval for the use of this viral gene therapy in diabetic patients, both type 1 and type 2,” Gittes says.
Learn more:Â Gene therapy restores normal blood glucose levels in mice with type 1 diabetes
From the Red Cross: “Everything you need to know about bloody types, why they’re so important, and what you can expect if you donate them.”
The Latest on: Type 1 diabetes
[google_news title=”” keyword=”type 1 diabetes” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Type 1 diabetes
- How Do You Develop Diabetes Type 1? A Review By Doctorson May 14, 2024 at 2:28 pm
Expert opinion from Sarath Chandr Rellu MBBS · 2 years of experience · India Diabetes type—1 is insulin-dependent diabetes mellitus, in which there is little or no insulin production from pancreas.
- Alzheimer’s biomarkers observed in young people with diabeteson May 14, 2024 at 8:55 am
New research shows that adolescents and young adults with type 1 or type 2 diabetes may be at higher risk of developing Alzheimer’s disease. The findings align with increasing evidence showing a link ...
- Rock Type One event harnesses music in quest for diabetes cureon May 14, 2024 at 2:10 am
Rock Type One to None will happen at Dreamland Bar-B-Q at the Centre Of Tallahassee from 4-7 p.m. Saturday, May 18.
- 'DWTS' pro Rylee Arnold opens up on living with Type 1 diabetes: 'Taught me so much about myself'on May 13, 2024 at 9:37 am
"Dancing with the Stars" pro Rylee Arnold is opening up about living with diabetes, writing she is "incredibly grateful for the strength it has given me," in an Instagram post on Monday. Arnold ...
- Glucose Level Fluctuations Tied to Cognitive Impairment in Type 1 Diabeteson May 13, 2024 at 7:18 am
Researchers sought to determine the cognitive performance of patients with both low and high glucose levels, as well as identify the characteristics predictive of differences in cognitive ...
- Breakthrough treatment offers hope for Type 1 diabetes patientson May 10, 2024 at 8:42 pm
With Tzield offering newfound optimism for Type 1 diabetes patients, Holdt's story serves as a beacon of hope, illustrating the potential of medical advancements to enhance quality of life. Holdt said ...
- AVAnT1A study: Investigating early COVID-19 vaccination and type 1 diabetes risk in high-risk childrenon May 8, 2024 at 8:29 pm
Type 1 diabetes is an autoimmune disease that leads to disrupted glucose metabolism. It requires lifelong insulin therapy. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) ...
- Cell therapy fails to slow early type 1 diabetes, but safety is establishedon May 8, 2024 at 11:00 am
Despite the negative finding, researchers said there is still promise in the strategy of amplifying and infusing the immune cells of newly diagnosed type 1 diabetes patients.
- Don't Overlook Cardiovascular Risk in Type 1 Diabeteson May 8, 2024 at 7:56 am
Cardiovascular disease management is an often overlooked but critical aspect of care for people with type 1 diabetes, authors of a new review paper said. Cardiovascular disease is the most common ...
- SARS-CoV-2 and type 1 diabetes in children: new study aims to explore the relationshipon May 7, 2024 at 5:00 pm
Type 1 diabetes is an autoimmune disease that leads to disrupted glucose metabolism. It requires lifelong insulin therapy. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) ...
via Bing News